Treos Bio Ltd., a London-based company developing precision peptide cancer vaccines coupled with companion diagnostics, has enlisted Pharmaceutical Product Development LLC to manage a phase I trial of PolyPEPI-1018, its lead vaccine for colorectal cancer. Once an investigational new drug application the company is filing is accepted, the trial is expected to start by late January 2018.